Copyright
©The Author(s) 2023.
World J Gastroenterol. Nov 7, 2023; 29(41): 5641-5656
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641
Table 2 Summary of overall survival
| All patients (n = 55) | Group A (n = 20) | Group B (n = 21) | Group C (n = 14) | |
| Patients with event | 16 (29.1%) | 8 (40.0%) | 4 (19.0%) | 4 (28.6%) |
| Patients without event | 39 (70.9%) | 12 (60.0%) | 17 (81.0%) | 10 (71.4%) |
| Time to event (mo) | ||||
| Median | - | - | - | - |
| 95%CI | 27.0, - | 9.0, - | 27.0, - | 12.0, - |
| 25% and 75%-ile | 15.50, - | 10.50, - | 27.00, - | 12.50, - |
| Min-max | 0.5-39 | 5-26 | 2.6-39 | 0.5-35 |
| 12 mo probability (95%CI) | 78.8 (65.1-87.7) | 65.0 (40.3-81.5) | 95.0 (69.5-99.3) | 75.0 (40.8-91.2) |
| 18 mo probability (95%CI) | 72.7 (58.3-82.9) | 60.0 (35.7-77.6) | 89.7 (64.8-97.3) | 66.7 (33.7-86.0) |
- Citation: Wang HC, Huang X, Chen J, Li Y, Cong Y, Qu BL, Feng SQ, Liu F. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world. World J Gastroenterol 2023; 29(41): 5641-5656
- URL: https://www.wjgnet.com/1007-9327/full/v29/i41/5641.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i41.5641